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Abstract THU0088 – Figure 1. Cumulative incidence of RA in the SOS study stratified by
baseline adiponectin
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Background: Novel biomarkers have been described in rheumatoid arthri-
tis (RA) patients, including antibodies to carbamylated proteins (anti-CarP)
and to protein-arginine deiminases (PAD). Anti-PAD4 antibodies are asso-
ciated with anti-citrullinated protein antibodies (ACPA) and worse baseline
radiographic joint damage [1]. A subset of anti-PAD4 antibodies that
cross-react with PAD3 and are associated with erosive disease, ACPA
and progress despite treatment have also been described [1].
Objectives: To evaluate several novel RA markers in a cohort of RA
and controls and their association with erosive disease and biological
treatment use in RA.
Methods: Sera from 116 RA patients [63 young onset RA (YORA) and
53 elderly onset RA (EORA)] and 155 controls [134 polymyalgia rheuma-
tica (PMR) patients and 21 healthy individuals (HI) older than 60 years
old] were included. Information on erosion status and biological treatment
was available for 56 of the RA patients. The samples were tested for
anti-PAD3 and anti-PAD4 IgG using the novel particle-based multi-analyte
technology (PMAT, research use only, RUO), as well as for ACPA
[CCP3 IgG ELISA and chemiluminescent immunoassay (CIA)] and anti-
CarP IgG (ELISA, RUO).
Results: Significantly higher levels of anti-PAD3, anti-PAD4 and ACPA
(ELISA and CIA) but not CarP were observed in YORA vs. EORA
(p<0.0001 for anti-PAD3 and ACPA ELISA and CIA, p=0.0016 for anti-
PAD4). In the RA patients with erosion and treatment information available,
anti-PAD4 antibody levels, but not ACPA, anti-CarP or anti-PAD3, were
significantly higher in patients on biologic treatment vs. patients that were
not on biologics (p=0.0017). Anti-PAD4 positive patients, were 10.1 [95%
CI 2.5-52.0, p=0.0002] times more likely to be on biologic treatment vs.
the negative group. Similarly, anti-PAD4 antibodies, but neither ACPA nor
anti-CarP or anti-PAD3, were also significantly higher in patients with joint
erosions (p=0.0354). All patients that were positive for anti-PAD4 antibodies
(n=21) had erosive disease. Anti-PAD4 positive patients, were 20.2 [95%
CI 1.1-363.2, p=0.0041] times more likely to have erosive disease.
Conclusion: Anti-PAD3, anti-PAD4 and ACPA are associated with disease
onset at an early age. Anti-PAD4 are associated with erosive disease
and biological treatment use in RA and represent a useful marker for
better patient stratification.
Abstract THU0089 – Figure 1. Association of anti-PAD4 antibodies with joint erosion status
(A) and to biological treatment use (B). Results are in Median Fluorescence Intensity (MFI).
P-values of the Mann-Whitney analysis are shown in red. Dashed line indicates the
preliminary cut-off of the assay. Number of positives and% within each subgroup are shown.
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Background: Longevity is the ultimate health outcome measure, incorpo-
rating treatment effectiveness as well as treatment safety. Randomized
Table 1. Prevalence of the assays in the different groups and in the entire cohort (percentage and number of individuals).
Assay/Group PMR HI YORA EORA RA (YORA+EORA) Total
% (N/total) 49% (134/271) 8% (21/271) 23% (63/271) 20% (53/271) 43% (116/271) 100% (271/271)
CCP3 ELISA 7% (9/134) 0% (0/21) 92% (58/63) 23% (12/53) 60% (70/116) 29% (79/271)
CCP3 CIA 7% (9/134) 0% (0/21) 95% (60/63) 25% (13/53) 63% (73/116) 30% (82/271)
CarP ELISA 41% (55/134) 14% (3/21) 49% (31/63) 62% (33/53) 55% (64/116) 45% (122/271)
PAD3 PMAT 1% (1/134) 5% (1/21) 16% (10/63) 0% (0/63) 9% (10/116) 4% (12/271)
PAD4 PMAT 10% (13/134) 14% (3/21) 38% (24/63) 13% (7/63) 27% (31/116) 17% (47/271)
PAD3+/4+ PMAT 1% (1/134) 0% (0/21) 16% (10/63) 0% (0/63) 9% (10/116) 4% (11/271)
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